Interferon gamma-1b

Generic Name
Interferon gamma-1b
Brand Names
Actimmune
Drug Type
Biotech
Chemical Formula
-
CAS Number
98059-61-1
Unique Ingredient Identifier
21K6M2I7AG
Background

Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography.
...

Indication

Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.

Associated Conditions
Chronic Granulomatous Disease (CGD), Severe, malignant Osteopetrosis
Associated Therapies
-
Clinical Trials
Related News

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

Phase 1
Completed
Conditions
Anterior Uveitis
Uveitis
Interventions
Drug: Interferon Gamma-1b
First Posted Date
2011-06-20
Last Posted Date
2012-10-08
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
5
Registration Number
NCT01376362
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cell Responses to IFN-gamma

Early Phase 1
Terminated
Conditions
Plaque Psoriasis
First Posted Date
2011-03-16
Last Posted Date
2013-03-05
Lead Sponsor
Rockefeller University
Target Recruit Count
2
Registration Number
NCT01317017
Locations
🇺🇸

Rockefeller University, New York, New York, United States

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

Phase 1
Completed
Conditions
Uveitis
First Posted Date
2009-07-22
Last Posted Date
2017-07-02
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
5
Registration Number
NCT00943982
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

First Posted Date
2004-01-30
Last Posted Date
2007-11-06
Lead Sponsor
InterMune
Target Recruit Count
91
Registration Number
NCT00076635
Locations
🇺🇸

Intermune Inc, Brisbane, California, United States

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Phase 1
Terminated
Conditions
Non-Hodgkin's Lymphoma
First Posted Date
2003-04-03
Last Posted Date
2007-11-01
Lead Sponsor
InterMune
Target Recruit Count
24
Registration Number
NCT00057447
Locations
🇺🇸

Intermune Inc, Brisbane, California, United States

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

Phase 3
Terminated
Conditions
Ovarian Carcinoma
Peritoneal Carcinoma
First Posted Date
2002-10-11
Last Posted Date
2007-11-01
Lead Sponsor
InterMune
Target Recruit Count
847
Registration Number
NCT00047632
Locations
🇺🇸

InterMune, Inc., Brisbane, California, United States

Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection

Phase 2
Terminated
Conditions
Lung Infection
First Posted Date
2002-08-12
Last Posted Date
2007-11-01
Lead Sponsor
InterMune
Target Recruit Count
100
Registration Number
NCT00043355

Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

Phase 1
Completed
Conditions
Cystic Fibrosis
First Posted Date
2002-08-12
Last Posted Date
2007-11-01
Lead Sponsor
InterMune
Target Recruit Count
51
Registration Number
NCT00043342

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Phase 1
Completed
Conditions
Cystic Fibrosis
First Posted Date
2002-08-09
Last Posted Date
2007-11-01
Lead Sponsor
InterMune
Target Recruit Count
66
Registration Number
NCT00043316

Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

Phase 2
Completed
Conditions
Liver Fibrosis
Cirrhosis
First Posted Date
2002-08-09
Last Posted Date
2007-11-01
Lead Sponsor
InterMune
Target Recruit Count
502
Registration Number
NCT00043303
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy